| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| flecainide acetate | Injection, solution | 10 mg/mL | Current | Unavailable | Manufacturing | 4/04/2025 |
| midazolam | Injection, solution | 5 mg/mL | Current | Limited Availability | Manufacturing | 4/04/2025 |
| benzathine benzylpenicillin tetrahydrate | Injection, suspension | 1200000 USP Unit | Anticipated | Available | Manufacturing | 4/04/2025 |
| olanzapine | Tablet, film coated | 10 mg | Current | Limited Availability | Manufacturing | 4/04/2025 |
| midazolam | Injection, solution | 5 mg | Current | Limited Availability | Manufacturing | 4/04/2025 |
| glyceryl trinitrate | Injection, concentrated | 50 mg | Resolved | Available | Manufacturing | 4/04/2025 |
| Belimumab | Injection, powder for | 120 mg | Resolved | Available | Manufacturing | 4/04/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | 1 mg | Current | Unavailable | Manufacturing | 4/04/2025 |
| montelukast sodium | Tablet, film coated | 10.4 mg | Anticipated | Available | Manufacturing | 4/04/2025 |
| praziquantel | Tablet, film coated | 600 mg | Discontinued | Reduction in supply until supply is exhausted | Manufacturing | 4/04/2025 |
| naproxen | Oral Liquid, suspension | 25 mg/mL | Anticipated | Available | Manufacturing | 4/04/2025 |
| simvastatin | Tablet, film coated | 80 mg | Current | Unavailable | Manufacturing | 4/04/2025 |
| rabeprazole sodium | Tablet, enteric coated | 20 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 4/04/2025 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Limited Availability | Unexpected increase in consumer demand | 4/04/2025 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Unavailable | Unexpected increase in consumer demand | 4/04/2025 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Unavailable | Manufacturing | 4/04/2025 |
| clonidine hydrochloride | Tablet | 100 microgram | Current | Unavailable | Unexpected increase in consumer demand | 4/04/2025 |
| risperidone | Tablet, film coated | 1 mg | Resolved | Available | Manufacturing | 4/04/2025 |
| levothyroxine sodium | Tablet | .05 mg | Current | Unavailable | Manufacturing | 4/04/2025 |
| levothyroxine sodium | Tablet | .2 mg | Current | Unavailable | Manufacturing | 4/04/2025 |
| levothyroxine sodium | Tablet | .1 mg | Current | Unavailable | Manufacturing | 4/04/2025 |
| levothyroxine sodium | Tablet | .075 mg | Current | Unavailable | Manufacturing | 4/04/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 21.688 mg | Current | Limited Availability | Manufacturing | 4/04/2025 |
| rivaroxaban | Tablet, film coated | 20 mg | Current | Unavailable | Manufacturing | 4/04/2025 |
| metoprolol tartrate | Tablet, uncoated | 50 mg | Anticipated | Available | Manufacturing | 4/04/2025 |
| sodium chloride | Injection, intravenous infusion | 9 g/L | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 4/04/2025 |
| sodium chloride | Injection, solution | 90 mg | Current | Limited Availability | Manufacturing | 4/04/2025 |
| midazolam | Injection, solution | 5 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 4/04/2025 |
| ropivacaine hydrochloride~fentanyl citrate | Injection, solution | 2 mg/mL~3.14 microgram/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 4/04/2025 |
| ropivacaine hydrochloride~fentanyl citrate | Injection, solution | 2 mg/mL~3.14 microgram/mL | Discontinued | Unavailable | Commercial Changes / Commercial viability | 4/04/2025 |
| ropivacaine hydrochloride~fentanyl citrate | Injection, solution | 2 mg/mL~6.28 microgram/mL | Discontinued | Unavailable | Commercial Changes / Commercial viability | 4/04/2025 |
| fentanyl citrate~ropivacaine hydrochloride | Injection, solution | 6.28 microgram/mL~2 mg/mL | Discontinued | Unavailable | Commercial Changes / Commercial viability | 4/04/2025 |
| propofol | Injection, emulsion | 10 mg/mL | Anticipated | Available | Manufacturing | 4/04/2025 |
| clarithromycin | Tablet, film coated | 250 mg | Current | Unavailable | Manufacturing | 4/04/2025 |
| nizatidine | Capsule | 150 mg | Current | Limited Availability | Manufacturing | 4/04/2025 |
| bupivacaine hydrochloride monohydrate | Injection, solution | 52.7 mg | Current | Unavailable | Unexpected increase in consumer demand | 3/04/2025 |
| gentamicin | Injection, solution | 80 mg | Current | Unavailable | Manufacturing | 3/04/2025 |
| olanzapine pamoate monohydrate | Injection, powder for | 931 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 3/04/2025 |
| olanzapine pamoate monohydrate | Injection, powder for | 690 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 3/04/2025 |
| olanzapine pamoate monohydrate | Injection, powder for | 483 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 3/04/2025 |
| anastrozole | Tablet, film coated | 1 mg | Resolved | Available | Manufacturing | 3/04/2025 |
| mycophenolate mofetil | Tablet, film coated | 500 mg | Current | Limited Availability | Manufacturing | 3/04/2025 |
| clonidine hydrochloride | Tablet, uncoated | 100 microgram | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 3/04/2025 |
| trandolapril | Capsule, hard | 1 mg | Current | Unavailable | Manufacturing | 3/04/2025 |
| trandolapril | Capsule, hard | 2 mg | Current | Unavailable | Manufacturing | 3/04/2025 |
| trandolapril | Capsule, hard | 4 mg | Current | Unavailable | Manufacturing | 3/04/2025 |
| amlodipine besilate~atorvastatin calcium trihydrate | Tablet, film coated | 13.88 mg~21.688 mg | Resolved | Available | Manufacturing | 3/04/2025 |
| noradrenaline (norepinephrine) acid tartrate monohydrate | Injection, concentrated | 4 mg | Current | Limited Availability | Manufacturing | 3/04/2025 |
| atomoxetine hydrochloride | Capsule, hard | 45.72 mg | Current | Unavailable | Manufacturing | 3/04/2025 |
| dosulepin (dothiepin) hydrochloride | Tablet, film coated | 75 mg | Resolved | Available | Manufacturing | 3/04/2025 |
| acamprosate calcium | Tablet, enteric coated | 333 mg | Resolved | Available | Unexpected increase in consumer demand | 3/04/2025 |
| ezetimibe~atorvastatin calcium trihydrate | Tablet, film coated | 10 mg~82.725 mg | Current | Unavailable | Manufacturing | 3/04/2025 |
| ezetimibe~atorvastatin calcium trihydrate | Tablet, film coated | 10 mg~41.363 mg | Current | Unavailable | Manufacturing | 3/04/2025 |
| ezetimibe~atorvastatin calcium trihydrate | Tablet, film coated | 10 mg~20.681 mg | Current | Unavailable | Manufacturing | 3/04/2025 |
| Semaglutide | Injection, solution | 1.34 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 3/04/2025 |
| Semaglutide | Injection, solution | 1.34 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 3/04/2025 |
| deferasirox | Tablet, film coated | 90 mg | Anticipated | Available | Manufacturing | 3/04/2025 |
| estradiol~norethisterone acetate~estradiol | Drug delivery system, transdermal | .78 mg~2.7 mg~.62 mg | Current | Unavailable | Manufacturing | 3/04/2025 |
| estradiol | Drug delivery system, transdermal | .39 mg | Current | Unavailable | Manufacturing | 3/04/2025 |
| estradiol | Drug delivery system, transdermal | 1.56 mg | Current | Unavailable | Manufacturing | 3/04/2025 |
| paracetamol | Tablet, modified release | 665 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 3/04/2025 |
| tirzepatide | Injection, solution | 5 mg | Current | Unavailable | Commercial Changes / Commercial viability | 3/04/2025 |
| tirzepatide | Injection, solution | 7.5 mg | Current | Unavailable | Commercial Changes / Commercial viability | 3/04/2025 |
| tirzepatide | Injection, solution | 12.5 mg | Current | Unavailable | Commercial Changes / Commercial viability | 3/04/2025 |
| tirzepatide | Injection, solution | 10 mg | Current | Unavailable | Commercial Changes / Commercial viability | 3/04/2025 |
| tirzepatide | Injection, solution | 15 mg | Current | Unavailable | Commercial Changes / Commercial viability | 3/04/2025 |
| tirzepatide | Injection, solution | 2.5 mg | Current | Unavailable | Commercial Changes / Commercial viability | 3/04/2025 |
| carboplatin | Injection, solution | 10 mg/mL | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 3/04/2025 |
| doxorubicin hydrochloride | Injection, concentrated | 20 mg | Anticipated | Available | Manufacturing | 3/04/2025 |
| gemfibrozil | Tablet, film coated | 600 mg | Current | Unavailable | Manufacturing | 3/04/2025 |
| estradiol hemihydrate | Drug delivery system, transdermal | 3.09 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 3/04/2025 |
| clonidine hydrochloride | Tablet, uncoated | 150 microgram | Current | Limited Availability | Unexpected increase in consumer demand | 3/04/2025 |
| reboxetine mesilate | Tablet, uncoated | 5.224 mg | Anticipated | Available | Manufacturing | 3/04/2025 |
| betiatide | Injection, powder for | 1 mg | Current | Limited Availability | Manufacturing | 2/04/2025 |
| adrenaline (epinephrine) acid tartrate | Injection, solution | 1.82 mg/mL | Current | Unavailable | Manufacturing | 2/04/2025 |
| sugammadex sodium | Injection, solution | 217.6 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 2/04/2025 |
| sugammadex sodium | Injection, solution | 544 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 2/04/2025 |
| fentanyl | Drug delivery system, transdermal | 8.4 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 2/04/2025 |
| azithromycin dihydrate | Tablet, film coated | 524.1 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 2/04/2025 |
| levetiracetam | Tablet, film coated | 1000 mg | Resolved | Available | Manufacturing | 2/04/2025 |
| carbidopa monohydrate~entacapone~levodopa | Tablet, film coated | 33.75 mg~200 mg~125 mg | Current | Limited Availability | Manufacturing | 2/04/2025 |
| hydrochlorothiazide~olmesartan medoxomil~amlodipine besilate | Tablet | 12.5 mg~20 mg~6.944 mg | Resolved | Available | Manufacturing | 2/04/2025 |
| olmesartan medoxomil~amlodipine besilate~hydrochlorothiazide | Tablet | 40 mg~6.944 mg~12.5 mg | Current | Limited Availability | Manufacturing | 2/04/2025 |
| adrenaline (epinephrine) acid tartrate | Injection, solution | 182 microgram/mL | Current | Unavailable | Manufacturing | 2/04/2025 |
| morphine hydrochloride trihydrate | Injection, solution | 20 mg/mL | Resolved | Available | Manufacturing | 2/04/2025 |
| atomoxetine hydrochloride | Capsule, hard | 91.44 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 2/04/2025 |
| fluorouracil | Injection, solution | 50 mg/mL | Current | Unavailable | Manufacturing | 2/04/2025 |
| emtricitabine~tenofovir disoproxil succinate | Tablet, film coated | 200 mg~300.6 mg | Resolved | Available | Manufacturing | 2/04/2025 |
| deferasirox | Tablet, film coated | 360 mg | Current | Unavailable | Manufacturing | 2/04/2025 |
| enoxaparin sodium | Injection, solution | 150 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 2/04/2025 |
| heparin sodium | Injection, solution | 1000 IU/mL | Resolved | Available | Manufacturing | 2/04/2025 |
| clopidogrel hydrogen sulfate | Tablet, film coated | 97.875 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 1/04/2025 |
| fentanyl | Drug delivery system, transdermal | 16.8 mg | Resolved | Available | Manufacturing | 1/04/2025 |
| risedronate sodium | Tablet, film coated | 35 mg | Current | Unavailable | Manufacturing | 1/04/2025 |
| propofol | Injection, emulsion | 10 g/L | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 1/04/2025 |
| amlodipine besilate~olmesartan medoxomil~hydrochlorothiazide | Tablet | 6.944 mg~40 mg~25 mg | Resolved | Available | Manufacturing | 1/04/2025 |
| duloxetine hydrochloride | Capsule, enteric | 67.3 mg | Resolved | Available | Manufacturing | 1/04/2025 |
| sodium iodide(131I) | Oral Liquid, solution | 50 MBq | Anticipated | Available | Manufacturing | 1/04/2025 |
| sodium iodide(131I) | Capsule, hard | 50 MBq | Anticipated | Available | Manufacturing | 1/04/2025 |
| fenofibrate | Tablet, film coated | 145 mg | Resolved | Available | Manufacturing | 1/04/2025 |
| emtricitabine~efavirenz~tenofovir disoproxil maleate | Tablet, film coated | 200 mg~600 mg~300 mg | Current | Unavailable | Manufacturing | 1/04/2025 |
| timolol maleate | Eye Drops, solution | 6.83 mg/mL | Current | Unavailable | Commercial Changes / Commercial viability | 1/04/2025 |
| benzathine benzylpenicillin tetrahydrate | Injection, suspension | 600000 USP Unit | Current | Unavailable | Manufacturing | 1/04/2025 |
| rivaroxaban | Tablet, film coated | 10 mg | Current | Unavailable | Manufacturing | 1/04/2025 |
| dasatinib propylene glycol | Tablet, film coated | 58 mg | Resolved | Available | Manufacturing | 1/04/2025 |
| dasatinib propylene glycol | Tablet, film coated | 81.2 mg | Resolved | Available | Manufacturing | 1/04/2025 |
| dasatinib propylene glycol | Tablet, film coated | 116 mg | Resolved | Available | Manufacturing | 1/04/2025 |
| adrenaline (epinephrine) | Injection, solution | 500 microgram | Anticipated | Available | Manufacturing | 1/04/2025 |
| rifampicin | Capsule, hard | 300 mg | Current | Unavailable | Manufacturing | 1/04/2025 |
| sodium iodide(131I) | Oral Liquid, solution | 1201 MBq | Anticipated | Available | Manufacturing | 1/04/2025 |
| sodium pertechnetate(99mTc) | Injection, solution | 20 GBq | Anticipated | Available | Manufacturing | 1/04/2025 |
| bicisate dihydrochloride | Injection, powder for | .9 mg | Current | Unavailable | Manufacturing | 1/04/2025 |
| sodium pertechnetate(99mTc) | Injection | 370 GBq | Anticipated | Available | Manufacturing | 1/04/2025 |
| olanzapine | Injection, powder for | 10 mg | Current | Limited Availability | Unexpected increase in consumer demand | 1/04/2025 |
| clopidogrel hydrogen sulfate | Tablet, film coated | 97.875 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 1/04/2025 |
| bupivacaine hydrochloride | Injection, solution | 2.5 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 31/03/2025 |
| amlodipine besilate | Tablet, uncoated | 7 mg | Anticipated | Available | Manufacturing | 31/03/2025 |
| bicalutamide | Tablet, film coated | 50 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 31/03/2025 |
| venlafaxine hydrochloride | Capsule, modified release | 169.71 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 31/03/2025 |
| bisoprolol fumarate | Tablet | 2.5 mg | Current | Limited Availability | Manufacturing | 31/03/2025 |
| ondansetron hydrochloride dihydrate | Tablet, film coated | 9.972 mg | Resolved | Available | Unexpected increase in consumer demand | 31/03/2025 |
| finasteride | Tablet, film coated | 1 mg | Anticipated | Available | Manufacturing | 31/03/2025 |
| quetiapine fumarate | Tablet, modified release | 57.565 mg | Anticipated | Available | Unexpected increase in consumer demand | 31/03/2025 |
| raloxifene hydrochloride | Tablet, film coated | 60 mg | Current | Unavailable | Unexpected increase in consumer demand | 31/03/2025 |
| acarbose | Tablet | 100 mg | Resolved | Available | Manufacturing | 31/03/2025 |
| acarbose | Tablet | 50 mg | Resolved | Available | Manufacturing | 31/03/2025 |
| amiodarone hydrochloride | Injection, solution | 150 mg | Current | Limited Availability | Manufacturing | 31/03/2025 |
| tenofovir disoproxil maleate | Tablet, film coated | 300 mg | Current | Unavailable | Manufacturing | 31/03/2025 |
| tenofovir disoproxil maleate~emtricitabine | Tablet, film coated | 300 mg~200 mg | Current | Limited Availability | Manufacturing | 31/03/2025 |
| armodafinil | Tablet, uncoated | 50 mg | Current | Limited Availability | Manufacturing | 31/03/2025 |
| prasugrel | Tablet, film coated | 5 mg | Current | Unavailable | Manufacturing | 31/03/2025 |
| spironolactone | Tablet, uncoated | 25 mg | Current | Unavailable | Manufacturing | 31/03/2025 |
| ropivacaine hydrochloride | Injection, solution | 2 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 31/03/2025 |
2025年4月7日